Literature DB >> 12663459

Glucose allostasis.

Michael Stumvoll1, P Antonio Tataranni, Norbert Stefan, Barbora Vozarova, Clifton Bogardus.   

Abstract

In many organisms, normoglycemia is achieved by a tight coupling of nutrient-stimulated insulin secretion in the pancreatic beta-cell (acute insulin response [AIR]) and the metabolic action of insulin to stimulate glucose disposal (insulin action [M]). It is widely accepted that in healthy individuals with normal glucose tolerance, normoglycemia can always be maintained by compensatorily increasing AIR in response to decreasing M (and vice versa). This has been mathematically described by the hyperbolic relationship between AIR and M and referred to as glucose homeostasis, with glucose concentration assumed to remain constant along the hyperbola. Conceivably, glucose is one of the signals stimulating AIR in response to decreasing M. Hypothetically, as with any normally functioning feed-forward system, AIR should not fully compensate for worsening M, since this would remove the stimulus for the compensation. We provide evidence from cross-sectional, longitudinal, and prospective data from Pima Indians (n = 413) and Caucasians (n = 60) that fasting and postprandial glucose concentrations increase with decreasing M despite normal compensation of AIR. For this physiologic adaptation to chronic stress (insulin resistance), we propose to use the term "glucose allostasis." Allostasis (stability through change) ensures the continued homeostatic response (stability through staying the same) to acute stress at some cumulative costs to the system. With increasing severity and over time, the allostatic load (increase in glycemia) may have pathological consequences, such as the development of type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663459     DOI: 10.2337/diabetes.52.4.903

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  29 in total

1.  The changing phenotype of the human species (affluent variety).

Authors:  E A M Gale
Journal:  Diabetologia       Date:  2004-07-23       Impact factor: 10.122

Review 2.  The role of glucose allostasis in type 2 diabetes.

Authors:  Michael Stumvoll; P Antonio Tataranni; Clifton Bogardus
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

3.  Innate immunity, insulin resistance and type 2 diabetes.

Authors:  J M Fernández-Real; J C Pickup
Journal:  Diabetologia       Date:  2011-11-30       Impact factor: 10.122

4.  The hyperbolic law--a 25-year perspective.

Authors:  M Stumvoll; P A Tataranni; C Bogardus
Journal:  Diabetologia       Date:  2005-02       Impact factor: 10.122

5.  Glucose allostasis: emperor's new clothes?

Authors:  T J Wilkin; B S Metcalf
Journal:  Diabetologia       Date:  2009-02-19       Impact factor: 10.122

6.  Glucose allostasis: disrobing common wisdom.

Authors:  M Stumvoll; C Bogardus
Journal:  Diabetologia       Date:  2009-03-06       Impact factor: 10.122

Review 7.  The disposition index: adjustment for peripheral vs. hepatic insulin sensitivity?

Authors:  K Faerch; C Brøns; A C Alibegovic; A Vaag
Journal:  J Physiol       Date:  2010-01-25       Impact factor: 5.182

Review 8.  Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions.

Authors:  Nicholas P Hays; Pietro R Galassetti; Robert H Coker
Journal:  Pharmacol Ther       Date:  2008-03-02       Impact factor: 12.310

9.  Exposure to recurrent sleep restriction in the setting of high caloric intake and physical inactivity results in increased insulin resistance and reduced glucose tolerance.

Authors:  Arlet V Nedeltcheva; Lynn Kessler; Jacqueline Imperial; Plamen D Penev
Journal:  J Clin Endocrinol Metab       Date:  2009-06-30       Impact factor: 5.958

10.  Twenty-four hour insulin secretion and beta cell NEFA oxidation in type 2 diabetic, morbidly obese patients before and after bariatric surgery.

Authors:  S Salinari; A Bertuzzi; A Iaconelli; M Manco; G Mingrone
Journal:  Diabetologia       Date:  2008-05-06       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.